These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 15205332

  • 1. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice.
    Kim SJ, Uehara H, Yazici S, Langley RR, He J, Tsan R, Fan D, Killion JJ, Fidler IJ.
    Cancer Res; 2004 Jun 15; 64(12):4201-8. PubMed ID: 15205332
    [Abstract] [Full Text] [Related]

  • 2. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice.
    Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ, Fidler IJ.
    Clin Cancer Res; 2003 Mar 15; 9(3):1200-10. PubMed ID: 12631626
    [Abstract] [Full Text] [Related]

  • 3. Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice.
    Yazici S, Kim SJ, Busby JE, He J, Thaker P, Yokoi K, Fan D, Fidler IJ.
    Prostate; 2005 Nov 01; 65(3):203-15. PubMed ID: 15948138
    [Abstract] [Full Text] [Related]

  • 4. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice.
    Weber KL, Doucet M, Price JE, Baker C, Kim SJ, Fidler IJ.
    Cancer Res; 2003 Jun 01; 63(11):2940-7. PubMed ID: 12782601
    [Abstract] [Full Text] [Related]

  • 5. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.
    Kim SJ, Uehara H, Yazici S, He J, Langley RR, Mathew P, Fan D, Fidler IJ.
    Cancer Res; 2005 May 01; 65(9):3707-15. PubMed ID: 15867366
    [Abstract] [Full Text] [Related]

  • 6. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
    Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, Tsan R, Killion JJ, Logothetis C, Mathew P, Fidler IJ.
    J Natl Cancer Inst; 2003 Mar 19; 95(6):458-70. PubMed ID: 12644539
    [Abstract] [Full Text] [Related]

  • 7. Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation.
    Younes MN, Yigitbasi OG, Park YW, Kim SJ, Jasser SA, Hawthorne VS, Yazici YD, Mandal M, Bekele BN, Bucana CD, Fidler IJ, Myers JN.
    Cancer Res; 2005 Jun 01; 65(11):4716-27. PubMed ID: 15930290
    [Abstract] [Full Text] [Related]

  • 8. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
    Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA, Dinney CP.
    Clin Cancer Res; 2002 Aug 01; 8(8):2714-24. PubMed ID: 12171905
    [Abstract] [Full Text] [Related]

  • 9. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
    Thaker PH, Yazici S, Nilsson MB, Yokoi K, Tsan RZ, He J, Kim SJ, Fidler IJ, Sood AK.
    Clin Cancer Res; 2005 Jul 01; 11(13):4923-33. PubMed ID: 16000591
    [Abstract] [Full Text] [Related]

  • 10. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
    Zhang F, Lee J, Lu S, Pettaway CA, Dong Z.
    Clin Cancer Res; 2005 Jun 15; 11(12):4512-20. PubMed ID: 15958637
    [Abstract] [Full Text] [Related]

  • 11. Combined low-dose imatinib mesylate and paclitaxel lack synergy in an experimental model of extra-osseous hormone-refractory prostate cancer.
    Corcoran NM, Costello AJ.
    BJU Int; 2005 Sep 15; 96(4):640-6. PubMed ID: 16104925
    [Abstract] [Full Text] [Related]

  • 12. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer.
    Younes MN, Yazici YD, Kim S, Jasser SA, El-Naggar AK, Myers JN.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3425-34. PubMed ID: 16740767
    [Abstract] [Full Text] [Related]

  • 13. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE.
    Clin Cancer Res; 2008 Apr 01; 14(7):2210-9. PubMed ID: 18381963
    [Abstract] [Full Text] [Related]

  • 14. Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer.
    Onn A, Isobe T, Wu W, Itasaka S, Shintani T, Shibuya K, Kenji Y, O'reilly MS, Fidler IJ, Herbst RS.
    Clin Cancer Res; 2004 Dec 15; 10(24):8613-9. PubMed ID: 15623645
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide.
    Shawver LK, Schwartz DP, Mann E, Chen H, Tsai J, Chu L, Taylorson L, Longhi M, Meredith S, Germain L, Jacobs JS, Tang C, Ullrich A, Berens ME, Hersh E, McMahon G, Hirth KP, Powell TJ.
    Clin Cancer Res; 1997 Jul 15; 3(7):1167-77. PubMed ID: 9815796
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
    Lev DC, Kim SJ, Onn A, Stone V, Nam DH, Yazici S, Fidler IJ, Price JE.
    Clin Cancer Res; 2005 Jan 01; 11(1):306-14. PubMed ID: 15671560
    [Abstract] [Full Text] [Related]

  • 17. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.
    Cancer Res; 2004 Jul 15; 64(14):4931-41. PubMed ID: 15256466
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.
    Pietras K, Rubin K, Sjöblom T, Buchdunger E, Sjöquist M, Heldin CH, Ostman A.
    Cancer Res; 2002 Oct 01; 62(19):5476-84. PubMed ID: 12359756
    [Abstract] [Full Text] [Related]

  • 19. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer.
    Kim SJ, Uehara H, Yazici S, Busby JE, Nakamura T, He J, Maya M, Logothetis C, Mathew P, Wang X, Do KA, Fan D, Fidler IJ.
    J Natl Cancer Inst; 2006 Jun 07; 98(11):783-93. PubMed ID: 16757703
    [Abstract] [Full Text] [Related]

  • 20. Renal cell carcinoma bone metastasis: epidermal growth factor receptor targeting.
    Weber KL, Doucet M, Price JE.
    Clin Orthop Relat Res; 2003 Oct 07; (415 Suppl):S86-94. PubMed ID: 14600596
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.